Portfolio news Archives

Synendos Reports Positive Phase 1 Results for SYT-510, Preparing for Phase 2

Basel, Switzerland - September 24, 2025, Synendos Therapeutics (“Synendos”), the clinical-stage biotech company developing breakthrough therapies for neuropsychiatric disorders, announced today topline results for its…

oliver.stula@baselarea.swiss24.09.2025

Portfolio news

metaLead Therapeutics Appoints David Urech as Member of the Board of Directors

Basel, Switzerland – September 23, 2025 – metaLead Therapeutics AG (“metaLead”) announces the appointment of David Urech, PhD, Founder and former Chief Executive Officer of…

oliver.stula@baselarea.swiss23.09.2025

Portfolio news

Gibela publishes groundbreaking research in Hepatology

We are pleased to share that the research of Gibela Therapeutics, our portfolio company, was featured on the cover of the Hepatology journal. The company is…

oliver.stula@baselarea.swiss14.08.2025

All Portfolio news

Synendos Appoints Dr. George Garibaldi as Chief Medical Officer

Basel, Switzerland – Synendos Therapeutics, the clinical-stage biotechnology company developing breakthrough therapies for neuropsychiatric disorders, announced the appointment of Dr. George Garibaldi as Chief Medical…

oliver.stula@baselarea.swiss12.08.2025

Portfolio news

We welcome BioDuro as our new domain partner

We’re excited to share our new partnership with BioDuro, a trusted CRDMO with a 29-year proven track record and strong reputation for delivering high-quality, end-to-end…

oliver.stula@baselarea.swiss25.07.2025

Portfolio news

Hemastatx joins BaseLaunch portfolio

We’re excited to welcome Hemastatx to our portfolio. Hemastatx, a spin-off from KU Leuven, has emerged from stealth with funding from BaseLaunch, Gemma Frisius Fund and…

oliver.stula@baselarea.swiss27.05.2025

Portfolio news

metaLead secures CHF 1 million investment to advance novel therapy for Wilson disease

Basel, Switzerland – May 5, 2025 – metaLead Therapeutics AG (metaLead), a pioneering biotech company developing next-generation metal-binding therapies, announced today that it has secured…

oliver.stula@baselarea.swiss06.05.2025

Portfolio news

Ilonov joins BaseLaunch portfolio

Ilonov is harnessing groundbreaking discoveries to revolutionize treatment for metabolic disorders. By harvesting novel targets discovered from breakthrough research on the human muscle secretome, the…

oliver.stula@baselarea.swiss13.03.2025

Portfolio news

Phialogics appoints Dr. Natalia Novac as Chief Executive Officer

Basel, Switzerland – 10 Feb, 2025, Phialogics AG has announced the appointment of Dr. Natalia Novac as Chief Executive Officer. Natalia has a great experience…

andy10.02.2025

Portfolio news

Gibela Therapeutics joins BaseLaunch portfolio

Gibela Therapeutics, a spin-off from the Cooperative Research Center in Biosciences (CIC bioGUNE), is pioneering RNA-based therapeutics for the treatment of liver diseases. The company,…

andy04.02.2025

Portfolio news

Synendos Reports Positive Phase 1 Results for SYT-510, Preparing for Phase 2

metaLead Therapeutics Appoints David Urech as Member of the Board of Directors

Gibela publishes groundbreaking research in Hepatology

Synendos Appoints Dr. George Garibaldi as Chief Medical Officer

We welcome BioDuro as our new domain partner

Hemastatx joins BaseLaunch portfolio

metaLead secures CHF 1 million investment to advance novel therapy for Wilson disease

Ilonov joins BaseLaunch portfolio

Phialogics appoints Dr. Natalia Novac as Chief Executive Officer

Gibela Therapeutics joins BaseLaunch portfolio

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us